ACLOTIN. 250 mg. 20 tablets
ACLOTIN. 250 mg. 20 tablets
Ticlopidin - 250mg
Lactose, corn starch , cellulose mikrokristapna stearic ??????????????????????????? , titanium dioxide ,
Film coating polyoxyethylene 6000
Properties and action
Ticlopidine inhibit aggregation ( clumping ) of platelets ( blood platelets ) and release la trombotsitarnite coagulation factors , preventing the formation of arterial and venous thrombi . Mechanism of action consists in keeping the dependence on ADP receptor glycoprotein (lib, Ilia) platelets. Thus ticlopidine impede platelet aggregation , prolongs the bleeding and reducing blood viscosity .
Prophylactically , in the case of threatening ischemic stroke in patients for whom treatment with acetylsalicylic acid is ineffective or are sensitive to it.
Hypersensitivity to ticlopidine, hemorrhagic diathesis , diseases which may cause bleeding ( gastric ulcer ) , acute hemorrhagic stroke , blood diseases occurring with increased duration of bleeding , leukopenia (decreased numbers of white blood cells) , thrombocytopenia ( decrease in the number of blood platelets ) , agranulocytosis ( increasing the number of agranulotsitite ), severe hepatic dysfunction .
Hematologic by the circulatory system are possible bleeding complications - bruising, nosebleeds , hematuria , postoperative bleeding. These symptoms usually resolve within 1-2 weeks after discontinuation .
Gastrointestinal side of the gastrointestinal tract
Gastrointestinal disorders, especially diarrhea and nausea at the beginning of treatment. In povechetoslluchai these effects are mild and rarely require discontinuation .
There was an increase the activity of alkaline phosphatase, aminotransferases and increase the concentration of cholesterol and triglycerides in plasma. Are described nemnogochisleni cases of hepatitis and congestive jaundice during the first months of treatment.
Dermatological by skin
Sometimes , an average of 11 days after the start of dosing can be skin rash , hives , itching . In some patients these phenomena are common and resolved upon discontinuation . Changes in Lab pokazateliKam worst side effects related offenses in the composition of the blood - neutropenia , agranulocytosis, pancytopenia and rare essential thrombocytopenia .
Should not be taken ticlopidine in combination with oral anticoagulants products , heparin, fibrinolytic agents , acetylsalicylic acid, and anti nesteroidnn products inhibiting platelet aggregation . Ticlopidine decreases slightly ( to 15% ) the concentration of digoxin in plasma and increases the concentration of theophylline. The products of neutralizing the hydrochloric acid , the concentration of ticlopidine decrease in plasma. Have much to vmnimava in applying ticlopidine instead of products metabolised in the liver by microsomal enzymes , and with propranolol , phenytoin and corticosteroids. No interaction of ticlopidine phenobarbital B adrenolitichni products, calcium channel blockers and diuretics.
Dosage and method of applied
Internally, one tablet (250mg) twice daily with meals .
Special warnings and special precautions for use
• During treatment, it is necessary to periodically monitor blood counts , especially during the first 12 weeks of treatment.
• Absent data on safety and efficacy in children .
• Carefully apply in patients concomitantly treated with pkortikosteroidi .
Pregnancy and lactation
Pregnancy and lactation are contraindicated for use of the product . Excreted in breast milk , and therefore not be given to nursing mothers.
Effects on ability to drive and use machines
Shelf life 3 years
Special precautions for storage
Protect from light and moisture. Do not store above 25C . Keep out of reach of children.
Blister containing 20 film-coated tablets in a carton with appropriate signage and information leaflet.